IXICO plc (IXI) AI Stock Analysis

• Market Cap: £7.30M
• Dividend Yield: N/A
• Average Volume (3M): 33.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: -13.49%
• EPS Growth: -69.67%
• Country: UK
• Employees: 81
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 92,668,594
• 10 Day Avg. Volume: 24,120
• 30 Day Avg. Volume: 33,932
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.53
• Price to Cash Flow (P/CF): -4.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

IXICO plc's stock is currently under pressure due to financial struggles and negative technical indicators. While new contracts in the imaging sector offer future revenue opportunities, the current financial position and market sentiment present significant challenges.

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc (IXI) is a UK-based company specializing in advanced data analytics and neuroimaging solutions for the pharmaceutical and biotechnology sectors. The company leverages its proprietary technology platform to offer data management, analysis, and interpretation services that support clinical trials and research in neurological diseases, including Alzheimer's, Parkinson's, and Huntington's. By providing comprehensive insights into brain health, IXICO aims to enhance the development and assessment of therapeutics for neurological conditions.

How the Company Makes Money

IXICO plc generates revenue primarily through its service contracts with pharmaceutical and biotechnology companies, which involve providing specialized data analytics and imaging solutions for clinical trials. The company's key revenue streams include fees for data analysis services, technology licensing, and consulting services related to the design and execution of clinical studies. Significant partnerships with major pharmaceutical companies contribute to its earnings by securing long-term contracts and collaborations. Additionally, IXICO's proprietary technology and expertise in neuroimaging are critical factors that bolster its market position and revenue generation capabilities.

IXICO plc Financial Statement Overview

Summary

IXICO plc is experiencing financial challenges, particularly in revenue generation and profitability. The decline in revenue growth and negative profit margins suggest operational difficulties. While the balance sheet remains strong with a high equity ratio, the cash flow position is concerning due to negative free cash flow and operational cash constraints. These factors reflect a need for strategic improvements to enhance profitability and cash flow generation.

Income Statement

The company has experienced a significant decline in revenue over the past year, with a negative revenue growth rate of 13.48% from 2023 to 2024. Both EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies. The net profit margin is also negative, reflecting ongoing struggles to achieve profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84.57%, indicating financial stability. However, the debt-to-equity ratio is low at 0.03, suggesting limited leverage which could restrict growth opportunities. Return on Equity is negative, further highlighting profitability issues.

Cash Flow

The company has faced a substantial decline in free cash flow, dropping from -1.66 million in 2023 to -2.20 million in 2024. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Additionally, the free cash flow to net income ratio suggests challenges in converting earnings to cash.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
6.00M	5.77M	6.67M	8.64M	9.19M	9.53M
	Gross Profit
2.59M	2.71M	3.27M	4.77M	5.53M	5.91M
	EBIT
-2.32M	-2.15M	-1.44M	111.00K	698.00K	236.00K
	EBITDA
-1.49M	-1.59M	-707.00K	750.00K	1.31M	674.00K
	Net Income Common Stockholders
-1.87M	-2.00M	-1.18M	1.03M	1.51M	952.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.45M	1.79M	4.03M	5.77M	6.68M	7.95M
	Total Assets
10.13M	11.19M	12.99M	14.65M	14.26M	12.10M
	Total Debt
0.00	314.00K	387.00K	516.00K	597.00K	213.00K
	Net Debt
-7.45M	-1.47M	-3.64M	-5.25M	-6.09M	-7.73M
	Total Liabilities
2.55M	1.72M	1.56M	2.16M	2.78M	2.98M
	Stockholders Equity
7.58M	9.46M	11.43M	12.49M	11.48M	9.12M
Cash Flow		Free Cash Flow
-2.05M	-2.20M	-1.66M	-815.00K	-1.54M	795.00K
	Operating Cash Flow
-982.00K	-1.73M	302.00K	1.43M	614.00K	1.94M
	Investing Cash Flow
-1.36M	-377.00K	-1.86M	-2.25M	-2.15M	-1.14M
	Financing Cash Flow
-209.00K	-134.00K	-156.00K	-114.00K	270.00K	-112.00K

IXICO plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Negative. The current price of 7.88 is below the 20-day moving average (MA) of 8.37, below the 50-day MA of 9.87, and below the 200-day MA of 9.72, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 16.57 is Positive, neither overbought nor oversold. The STOCH value of 11.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IXI.

IXICO plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNS	67 Neutral	£1.09B	147.63	-0.73%	1.99%	-0.22%	-111.98%
Sector *	48 Neutral	$6.46B	1.17	-48.25%	2.67%	19.50%	0.61%
IXI	41 Neutral	£7.30M	―	-19.15%	―	-13.49%	-69.67%
SCLP	36 Underperform	£85.53M	―	167.16%	―	-100.00%	-23.91%

IXICO plc Corporate Events

IXICO Secures New Contracts in Alzheimer’s and Huntington’s Disease Imaging

IXICO plc announced the signing of a new commercial contract for Alzheimer’s Disease imaging analysis with a leading biotechnology company and an additional project in Huntington’s Disease with an existing partner. The contracts, valued at over £0.5 million, will be recognized within a year and contribute to IXICO’s ‘Innovate, Lead, Scale’ strategy, potentially leading to further revenues. These agreements highlight IXICO’s status as a global neuroimaging market leader with a strong biomarker technology advantage.

IXICO’s AI Platform Advances Huntington’s Disease Research

IXICO plc has announced a significant milestone in Huntington’s Disease research by verifying its AI imaging platform, IXIQ.Ai, in collaboration with the Huntington’s Disease Imaging Harmonisation consortium. This achievement not only advances the understanding of Huntington’s Disease but also strengthens IXICO’s positioning in the biopharma industry by offering enhanced tools for imaging biomarkers and opening new revenue opportunities through expanded clinical trial biomarker analysis.

IXICO Issues Share Option Awards to Enhance Strategic Goals

IXICO plc has announced the issuance of share option awards for 7,413,488 shares, following approval by 99.76% of shareholders at the Annual General Meeting. This strategic move, discussed with major shareholders in October 2024, reflects the company’s commitment to enhancing its operational framework and aligns with its broader objectives in advancing neurological disorder therapies.

IXICO plc Secures Resolutions at AGM, Strengthening Governance

IXICO plc announced that all resolutions were passed at its recent Annual General Meeting, reflecting strong shareholder support. The approval of resolutions, including the re-election of key executives and the adoption of new articles, underscores IXICO’s strategic focus on enhancing corporate governance and operational efficiency, positively impacting its industry positioning and stakeholders.